Mycoplasma genitalium and Antimicrobial Resistance Among a Cohort of West African Men Who Have Sex With Men Using Preexposure Prophylaxis (CohMSM-PrEP ANRS 12369-Expertise France Study)

Abstract Background Antimicrobial resistance to macrolides and fluoroquinolones in Mycoplasma genitalium (MG) among men who have sex with men (MSM) is worryingly high in high-resource countries. Data in Africa are lacking. We aimed to assess the burden of MG including the presence of resistance-associated mutations (RAMs) in MG among MSM using human immunodeficiency virus preexposure prophylaxis in Burkina Faso, Côte d’Ivoire, Mali, and Togo. Methods MSM were included in a prospective cohort study (2017–2021). Molecular detection of MG in urine, anorectal, and pharyngeal samples was performed at baseline and after 6 and 12 months. Detection of RAMs to macrolides and fluoroquinolones was performed by sequencing the 23S ribosomal RNA, parC, and gyrA genes. A sample was found to be possibly resistant to fluoroquinolones if alterations were found in ParC position 83/87. Results Of 598 participants, 173 (28.9%) were positive at least once for MG and global point-prevalence was 19.4%. Interestingly, 238 of 250 (95.2%) infections were asymptomatic and 72 of 138 MG infections with follow-up data (52.2%) cleared during the study. Only 1 macrolide RAM was found (0.6%). Prevalence of fluoroquinolones RAMs was 11.3% overall, ranging from 2.4% in Burkina Faso to 17.5% in Mali. Conclusions Although MG was highly prevalent in these MSM, macrolide resistance was almost nonexistent. Nevertheless, >10% of the samples were possibly resistant to fluoroquinolones. Heterogeneity in the prevalence of fluoroquinolone RAMs between countries may be explained by different antimicrobial consumption in humans and animals.

[1]  S. Nzenze,et al.  A systematic review of antimicrobial resistance in Neisseria gonorrhoeae and Mycoplasma genitalium in sub-Saharan Africa , 2022, The Journal of antimicrobial chemotherapy.

[2]  M. Unemo,et al.  2021 European guideline on the management of Mycoplasma genitalium infections , 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

[3]  B. Vuylsteke,et al.  Worryingly high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in Mycoplasma genitalium among men who have sex with men with recurrent sexually transmitted infections , 2022, International journal of STD & AIDS.

[4]  S. Bruisten,et al.  Macrolide-Resistant Mycoplasma genitalium Impairs Clinical Improvement of Male Urethritis After Empirical Treatment , 2021, Sexually transmitted diseases.

[5]  C. Kenyon.  Positive Association between the Use of Quinolones in Food Animals and the Prevalence of Fluoroquinolone Resistance in E. coli and K. pneumoniae, A. baumannii and P. aeruginosa: A Global Ecological Analysis , 2021, Antibiotics.

[6]  C. Sindato,et al.  Antimicrobial Use and Resistance in Agriculture and Food Production Systems in Africa: A Systematic Review , 2021, Antibiotics.

[7]  K. Workowski,et al.  Sexually Transmitted Infections Treatment Guidelines, 2021 , 2021, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.

[8]  V. Calvez,et al.  Prevalence of cervical HPV infection, sexually transmitted infections and associated antimicrobial resistance in women attending cervical cancer screening in Mali. , 2021, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

[9]  B. Spire,et al.  HIV pre-exposure prophylaxis for men who have sex with men in west Africa: a multicountry demonstration study. , 2021, The lancet. HIV.

[10]  J. Buyze,et al.  The Population-Level Effect of Screening for Mycoplasma genitalium on Antimicrobial Resistance: A Quasi-Experimental Study , 2021, Sexually transmitted diseases.

[11]  Ravesh Singh,et al.  Lack of resistance to macrolides in Mycoplasma genitalium detected in South African pregnant women , 2021, Southern African journal of infectious diseases.

[12]  L. Hall,et al.  Non-prescription dispensing of antibiotic agents among community drug retail outlets in Sub-Saharan African countries: a systematic review and meta-analysis , 2021, Antimicrobial resistance and infection control.

[13]  C. Delaugerre,et al.  High Prevalence and High Rate of Antibiotic Resistance of Mycoplasma genitalium Infections in Men who Have Sex with Men. A Sub-Study of the ANRS Ipergay PrEP Trial. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  M. Lipsitch,et al.  Selection of Macrolide and Non-Macrolide Resistance with Mass Azithromycin Distribution: A Community-Randomized Trial , 2020, The New England journal of medicine.

[15]  C. Kenyon,et al.  Macrolide consumption and resistance in Mycoplasma genitalium. , 2020, The Lancet. Infectious diseases.

[16]  B. Vuylsteke,et al.  An alarming high prevalence of resistance-associated mutations to macrolides and fluoroquinolones in Mycoplasma genitalium in Belgium: results from samples collected between 2015 and 2018 , 2020, Sexually Transmitted Infections.

[17]  E. Klein,et al.  Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000-15: an analysis of pharmaceutical sales data. , 2020, The Lancet. Infectious diseases.

[18]  N. Low,et al.  Prevalence of mutations associated with resistance to macrolides and fluoroquinolones in Mycoplasma genitalium: a systematic review and meta-analysis. , 2020, The Lancet. Infectious diseases.

[19]  N. Low,et al.  Understanding the spread of de novo and transmitted macrolide-resistance in Mycoplasma genitalium , 2020, PeerJ.

[20]  W. V. Berghe,et al.  An alarming high prevalence of resistance associated mutations to macrolides and fluoroquinolones in Mycoplasma genitalium in Belgium: Results from samples collected between 2015-2018 , 2020 .

[21]  R. Kirkcaldy,et al.  Prevalence of Mycoplasma genitalium infection, antimicrobial resistance mutations and symptom resolution following treatment of urethritis. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  C. Kenyon,et al.  Gonococcal resistance can be viewed productively as part of a syndemic of antimicrobial resistance: an ecological analysis of 30 European countries , 2020, Antimicrobial Resistance & Infection Control.

[23]  H. Jessen,et al.  STI in times of PrEP: high prevalence of chlamydia, gonorrhea, and mycoplasma at different anatomic sites in men who have sex with men in Germany , 2020, BMC Infectious Diseases.

[24]  L. Vodstrcil,et al.  Prevalence of Mycoplasma genitalium by anatomical site in men who have sex with men: a systematic review and meta-analysis , 2019, Sexually Transmitted Infections.

[25]  S. Peel,et al.  Anorectal and Urogenital Mycoplasma Genitalium in Nigerian Men who have Sex with Men and Transgender Women: Prevalence, Incidence, and Association with HIV. , 2019, Sexually transmitted diseases.

[26]  F. Dabis,et al.  Incidence of sexually transmitted infections during pre-exposure prophylaxis for HIV: a worrying outcome at 2 years! , 2019, Sexually Transmitted Infections.

[27]  F. Dabis,et al.  High prevalence of Mycoplasma genitalium infection and macrolide resistance in patients enrolled in HIV pre-exposure prophylaxis program. , 2019, Medecine et maladies infectieuses.

[28]  D. Lewis,et al.  Macrolide and fluoroquinolone resistance-associated mutations in Mycoplasma genitalium in Johannesburg, South Africa, 2007–2014 , 2019, BMC Infectious Diseases.

[29]  R. Peters,et al.  Failure of syndromic management due to drug-resistant Mycoplasma genitalium infection in South Africa: a case report , 2019, International journal of STD & AIDS.

[30]  C. Charpentier,et al.  Prevalence of Human Papillomavirus, Human Immunodeficiency Virus, and Other Sexually Transmitted Infections Among Men Who Have Sex With Men in Togo: A National Cross-sectional Survey , 2019 .

[31]  B. Vuylsteke,et al.  Choosing Between Daily and Event-Driven Pre-exposure Prophylaxis: Results of a Belgian PrEP Demonstration Project , 2018, Journal of acquired immune deficiency syndromes.

[32]  N. Low,et al.  Prevalence of Mycoplasma genitalium in different population groups: systematic review andmeta-analysis , 2017, Sexually Transmitted Infections.

[33]  J. Jensen.  Mycoplasma genitalium: yet another challenging STI. , 2017, The Lancet. Infectious diseases.

[34]  F. Garrett,et al.  Which azithromycin regimen should be used for treating Mycoplasma genitalium? A meta-analysis , 2017, Sexually Transmitted Infections.

[35]  Chantal Quinten,et al.  ECDC/EFSA/EMA second joint report on the integrated analysis of the consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from humans and food‐producing animals , 2017, EFSA journal. European Food Safety Authority.

[36]  S. Morré,et al.  Prevalence and macrolide resistance of Mycoplasma genitalium in South African women. , 2015, Sexually transmitted diseases.

[37]  J. Jensen.  Protocol for the detection of Mycoplasma genitalium by PCR from clinical specimens and subsequent detection of macrolide resistance-mediating mutations in region V of the 23S rRNA gene. , 2012, Methods in molecular biology.

[38]  M. Yasuda,et al.  Emergence of clinical strains of Mycoplasma genitalium harbouring alterations in ParC associated with fluoroquinolone resistance. , 2010, International journal of antimicrobial agents.

[39]  S. Tabrizi,et al.  Azithromycin treatment failure in Mycoplasma genitalium-positive patients with nongonococcal urethritis is associated with induced macrolide resistance. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.